Figure 3From: Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing gliomaIn vivo antitumor activity of EGFRvIII/CAR+T cells. EGFRvIII expressing U87 cells were used for xenograft mouse model. EGFRvIII-bearing BALB/cA-nude mice received different treatments: group A, EGFRvIII/CAR+ T cells (IT); group B, EGFRvIII/CAR+ T cells (IV); group C, GFP+ T cells (IV); group D, PBS (IV). Results are expressed as a mean tumor volume (mm3±SD) with n = 5 for all groups. The standard deviation (SD) is represented by error bars.Back to article page